Despite many recent advances in prevention and treatment interventions for HIV and substance use, policymakers and providers have been forced to confront a persistent insufficiency of funds and to make difficult choices from among competing claims on scarce resources. In this renewal application, we propose to continue our work to address emerging questions about global HIV prevention, treatment, and priority setting in substance-using populations. We will extend our prior epidemiologic modeling work by assessing portfolios of prevention and treatment interventions, by addressing these interventions in the context of co-epidemics (HIV, hepatitis C virus infection, and tuberculosis), and by developing resource allocation tools. The goal of our work is to use epidemiologic modeling to help decision makers optimize population health by providing information on the comparative effectiveness, cost-effectiveness, and affordability of alternative portfolio investments.
Our aims are: 1. To estimate production functions that characterize the relationship between program expenditures and health-related outcomes, such as reductions in transmission risk for prevention programs and the delivery of services for treatment programs. 2. To develop model-based methods to translate the behavioral and biological impact of HIV-related interventions into epidemic outcomes, such as infections averted and years of life saved. 3. To determine how best to estimate health outcomes, costs, and cost-effectiveness of HIV and substance use interventions (for example, in the presence of co-epidemics). 4. To assess the individual- and population-level effectiveness, cost, cost-effectiveness, and budget impact of specific interventions aimed at preventing and treating HIV and substance use and related co-epidemics (e.g., HIV, HCV, and tuberculosis). 5. To inform the allocation of societal resources by examining the effectiveness and cost- effectiveness of portfolios of prevention and treatment interventions in the context of the regional epidemiology of disease. 6. To develop practical resource allocation tools for policymakers to assist them in making informed investments of resources in HIV and substance use treatment and prevention programs. Our proposed research will develop innovative epidemiologic modeling methods for assessing portfolios of interventions;critically evaluate promising prevention and treatment interventions;advance the state of the art in HIV planning and policy modeling;and provide planners with innovative tools to assist them in informed allocation of scarce resources for HIV and substance use prevention and treatment. The proposed work will enable us to have broad impact on HIV and substance use policy in the U.S. and internationally.

Public Health Relevance

The goal of our work is to use epidemiologic modeling to help decision makers optimize population health by providing information on the comparative effectiveness, cost-effectiveness, and affordability of interventions for HIV and substance use. Our proposed research will develop innovative epidemiologic modeling methods for assessing portfolios of interventions;critically evaluate promising prevention and treatment interventions;advance the state of the art in HIV planning and policy modeling;and provide planners with innovative tools to assist them in informed allocation of scarce resources for HIV and substance use prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
2R01DA015612-11
Application #
8410065
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Hartsock, Peter
Project Start
2002-09-25
Project End
2018-01-31
Budget Start
2013-05-01
Budget End
2014-01-31
Support Year
11
Fiscal Year
2013
Total Cost
$688,678
Indirect Cost
$200,932
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Gonsalves, Gregg S; Copple, J Tyler; Johnson, Tyler et al. (2018) Bayesian adaptive algorithms for locating HIV mobile testing services. BMC Med 16:155
Gonsalves, Gregg S; Crawford, Forrest W; Cleary, Paul D et al. (2018) An Adaptive Approach to Locating Mobile HIV Testing Services. Med Decis Making 38:262-272
Gonsalves, Gregg S; Crawford, Forrest W (2018) Dynamics of the HIV outbreak and response in Scott County, IN, USA, 2011-15: a modelling study. Lancet HIV 5:e569-e577
Rhines, Allison S; Feldman, Marcus W; Bendavid, Eran (2018) Modeling the implementation of population-level isoniazid preventive therapy for tuberculosis control in a high HIV-prevalence setting. AIDS 32:2129-2140
Wagner, Zachary; Heft-Neal, Sam; Bhutta, Zulfiqar A et al. (2018) Armed conflict and child mortality in Africa: a geospatial analysis. Lancet 392:857-865
Suen, Sze-Chuan; Brandeau, Margaret L; Goldhaber-Fiebert, Jeremy D (2018) Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment. Health Care Manag Sci 21:632-646
Burgos, Jose Luis; Cepeda, Javier A; Kahn, James G et al. (2018) Cost of provision of opioid substitution therapy provision in Tijuana, Mexico. Harm Reduct J 15:28
Fu, Rui; Owens, Douglas K; Brandeau, Margaret L (2018) Cost-effectiveness of alternative strategies for provision of HIV preexposure prophylaxis for people who inject drugs. AIDS 32:663-672
Pitt, Allison L; Humphreys, Keith; Brandeau, Margaret L (2018) Modeling Health Benefits and Harms of Public Policy Responses to the US Opioid Epidemic. Am J Public Health 108:1394-1400
Morozova, Olga; Cohen, Ted; Crawford, Forrest W (2018) Risk ratios for contagious outcomes. J R Soc Interface 15:

Showing the most recent 10 out of 159 publications